Elahere (Mirvetuximab Soravtansine)
Brand Names: Elahere
Methodology & AI Transparency ⓘ
Elahere (Mirvetuximab Soravtansine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Mirvetuximab Soravtansine (cross-referenced at /meds/mirvetuximab-soravtansine) and registered by ImmunoGen, Inc., Elahere operates as a prescription brand-name fda prescription therapeutic agent therapy (RxNorm 2621559; NDC 72903-853).
- 2 Real-world patient consensus: Commercial Elahere monograph (5 mg/mL Injection, Solution) cross-indexed with generic Mirvetuximab Soravtansine for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $228.10 discount cash to $604.46 walk-in retail (NADAC $3.0500/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Elahere (Mirvetuximab Soravtansine)): nausea (10.5%), diarrhea (7.8%), fatigue (8.2%).
Ask our AI Specialists anything about Elahere (Mirvetuximab Soravtansine)
Elahere (Mirvetuximab Soravtansine) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Mirvetuximab Soravtansine (cross-referenced at /meds/mirvetuximab-soravtansine) and registered by ImmunoGen, Inc., Elahere operates as a prescription brand-name fda prescription therapeutic agent therapy (RxNorm 2621559; NDC 72903-853). Under 2025-07-14 FDA labeling for 5 mg/mL Injection, Solution; 5%, 1 Indications and usage elahere: ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα).
Bioactive Mirvetuximab Soravtansine within Elahere governs fda prescription therapeutic agent target modulation involving CYP3A4 clearance pathways. Commercialized across 5 mg/mL Injection, Solution; 5% (registered by ImmunoGen, Inc., SPL 2025-07-14), Elahere combines branded dosage-form consistency (NDC 72903-853) with transparent cash-pay comparisons spanning $228.10 to $604.46.
Systemic exposure to Elahere (Mirvetuximab Soravtansine) reflects Complete (~100%) parenteral systemic delivery for Elahere (Mirvetuximab Soravtansine) (5 mg/mL Injection, Solution) absorption kinetics and phase i cyp3a4 hepatic clearance and subsequent renal metabolite filtration, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 9–13 hour t½ intervals for Elahere (Mirvetuximab Soravtansine) half-life window (rapid intravascular/parenteral onset within 15–45 minutes after elahere (mirvetuximab soravtansine) administration response profile).
Dosing protocols (5 mg/mL Injection, Solution or 5% or 6 mg) balance efficacy (83.00% patient satisfaction across 22 logs) against nausea (10.5% of reports), fatigue (8.2% of reports), diarrhea (7.8% of reports), with strict avoidance in previous anaphylactoid or exfoliative reaction attributed to elahere (mirvetuximab soravtansine); clinical scenarios where fda prescription therapeutic agent exposure from elahere (mirvetuximab soravtansine) poses unacceptable risk.
Systemic bioavailability and half-life of Elahere (Mirvetuximab Soravtansine) respond to strong CYP3A4 enzymatic inhibition or induction.
Verify medication reconciliation lists so Elahere (Mirvetuximab Soravtansine) is not inadvertently duplicated with another fda prescription therapeutic agent.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Elahere (Mirvetuximab Soravtansine)
- Clinical scenarios where fda prescription therapeutic agent exposure from Elahere (Mirvetuximab Soravtansine) poses unacceptable risk
Logged Side-Effect Incidence (22 Reports)
Elahere (Mirvetuximab Soravtansine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Elahere (Mirvetuximab Soravtansine))
Human clinical trial evidence for Elahere (Mirvetuximab Soravtansine) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Elahere (Mirvetuximab Soravtansine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.0500/unit (~$91.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $604.46 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $228.10 / mo | View logs ↓ |
Elahere (Mirvetuximab Soravtansine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Elahere (Mirvetuximab Soravtansine) RxNorm Concept ID | 2621559 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.0500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $604.46 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $228.10 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Elahere (Mirvetuximab Soravtansine) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Elahere (Mirvetuximab Soravtansine): FDA labeling (2025-07-14, NDC 72903-853), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Elahere (Mirvetuximab Soravtansine) community threads and patient logs by age, biological sex, dosage, and treatment duration.